Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Truvada PK Standards in Healthy Individuals
NCT03719053Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Oct 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoints: Plasma Tenofovir concentration at 24 hours and Peripheral Blood Mononuclear Cells Tenofovir diphosphate concentration at 24 hours. Started Oct 2018; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03719053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719053.